Early insights into predicted efficacy of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreak

This is a preview of the original article. Source: Nature.com · Kevin Cissy Nabukeera, Gradi Luakanda-Ndelemo, Syrus Semawule, Alisen Ayitewala, Pascal Adroba-Tandele, Andrew Walakira, Adrienne Amuri-Aziza, Daan Jansen, Ronald Galiwango, Eddy Kinganda-Lusamaki, Andrew Tebba, Christian Ngandu, Aloysious Ssemaganda, Olivier Tshiani-Mbaya, Stephen Kanyerezi, Judith Kyokushaba, Prince Akil-Bandali, Carol Makoha, Hellen Rosette Oundo, Servet Kimbonza, Stephen Balinandi, Daniel Mukadi-Bamuleka, Valeria Nakintu, Justus Nsio, Ibrahimm Mugerwa, Daniel Kadobera, Daniel Euriene, Sabue Mulangu, Ahidjo Ayouba, Micheal Eliu, Sam Gidudu, Henry Kyobe Bosa, Misaki Wayengera, Anne W. Rimoin, Benard Lubwama, Atek Kagirita, Steve Ahuka-Mundeke, Dieudonné Mwamba, Andrew Kambugu, Pontiano Kaleebu, Christian Happi, Laurens Liesenborghs, Miles W. Carroll, Piet Maes, Jean B. Nachega, Martine Peeters, Pierre Akilimali, Ronnie Bahatungire, Allan Muruta, Jason Kindrachuk, Andrew Rambaut, Daniel Kyabayinze, Charles Olaro, Koen Vercauteren, Jean-Jacques Muyembe-Tamfum, Susan Nabadda, Diana Atwine, Daudi Jjingo, Tony Wawina-Bokalanga, Placide Mbala-Kingebeni, Isaac Ssewanyana

Read the original article